Anacor Phase 2 Study Of Novel Topical Antifungal For Onychomycosis Demonstrates Efficacy

... Anacor Pharmaceuticals, a privately held pharmaceutical company, today announced the end-of-treatment results from a 60-patient, Phase 2, open-label study of 5 percent and 7.5percent solutions AN2690 in onychomycosis, a fungal infection of the nailand nail bed. At 6 months, halfway through the study, 50 percent ofpatients in the 7. [click link for full article] ...